The National Cancer Institute (NCI) findings in osteosarcoma, a form of bone cancer, are consistent with a preclinical study of CTCE-9908 conducted by researchers at Chemokine Therapeutics.
CTCE-9908 is designed to inhibit the growth and spread of certain common cancers with the potential for use with existing therapies (chemotherapy, surgery, and radiation) to improve treatment outcomes.
CTCE-9908 is an analog of SDF-1, a chemokine that has been shown to affect the growth and spread of cancer, and an antagonist of SDF-1 receptors, which are expressed in both stem cells and various common cancers.
The presence of these SDF-1 receptors on cancer cells allows the cancerous cells to migrate from the original cancer site to new sites that are rich in SDF-1, such as bone marrow, liver, and lungs, where they develop new blood vessels and form new tumors. CTCE-9908 binds competitively to the receptors on cancer cells, preventing the interaction of SDF-1 with the receptors.